3/23/24, 10:53 AM Revision 4

Revision 4						
#200 Phospho-IKk Antibody II	<b>α/β (Ser17</b>	6/180)			Il Signaling CHNOLOGY* 877-616-CELL (2355) orders@cellsignal.com 877-678-TECH (8324) info@cellsignal.com cellsignal.com	
3 Trask Lane   Danvers   Massachusetts   01923   USA						
For Research Use Only. Not for Use in Diagnostic Procedures.						
		sitivity: MW (kDa): ogenous 85 IKK-alpha IKK-beta		UniProt ID: #014920, #015111	Entrez-Gene Id: 3551, 1147	
Product Usage Information	Application Western Blo			Dilution 1:1000		
Storage		.0 mM sodium HEPES (pH t aliquot the antibody.	S (pH 7.5), 150 mM NaCl, 100 $\mu\text{g/ml}$ BSA and 50% glycerol. Store at –			
Specificity / Sensitivity			body II detects endogenous levels of IKK $\alpha$ and IKK $\beta$ only when 180 or Ser177 and Ser181, respectively.			
		ntibodies are produced by unding Ser177/181 of IKK( phy.				
Background	inhibitory IĸB phosphorylat pathway invo generally car subunits of th phosphorylat	The NF- $\kappa$ B/Rel transcription factors are present in the cytosol in an inactive state, complexed with the inhibitory IkB proteins (1-3). Most agents that activate NF- $\kappa$ B do so through a common pathway based on phosphorylation-induced, proteasome-mediated degradation of IkB (3-7). The key regulatory step in this pathway involves activation of a high molecular weight IkB kinase (IKK) complex whose catalysis is generally carried out by three tightly associated IKK subunits. IKK $\alpha$ and IKK $\beta$ serve as the catalytic subunits of the kinase and IKK $\gamma$ serves as the regulatory subunit (8,9). Activation of IKK depends upon phosphorylation at Ser177 and Ser181 in the activation loop of IKK $\beta$ (Ser176 and Ser180 in IKK $\alpha$ ), which causes conformational changes, resulting in kinase activation (10-13).				
2. Beg, A.A. and Bald 3. Finco, T.S. et al. (1 4. Brown, K. et al. (1 5. Brockman, J.A. et 6. Traenckner, E.B. et 7. Chen, Z.J. et al. (1 8. Zandi, E. et al. (19 9. Karin, M. (1999) C 10. DiDonato, J.A. et al 11. Mercurio, F. et al. 12. Johnson, L.N. et al		and Baldwin, A.S. (1993) ( et al. (1994) <i>Proc Natl Ac</i> et al. (1995) <i>Science</i> 267, , J.A. et al. (1995) <i>Mol Ce</i> er, E.B. et al. (1995) <i>EMBC</i> et al. (1996) <i>Cell</i> 84, 853 et al. (1997) <i>Cell</i> 91, 243-5 (1999) <i>Oncogene</i> 18, 686 J.A. et al. (1997) <i>Nature</i> 3 F. et al. (1997) <i>Science</i> 27 N. et al. (1996) <i>Cell</i> 85, 5	97) Cell 91, 243-52. Dicogene 18, 6867-74. al. (1997) Nature 388, 548-54. (1997) Science 278, 860-6.			
Species Reactivity	Species react	ivity is determined by testi	ing in at least one ap	proved application (e.g., w	vestern blot).	
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted pr 0.1% Tween® 20 at 4°C with gentle shaking, overnight.			5% w/v BSA, 1X TBS,	
Applications Key	WB: Westerr	n Blotting				
Cross-Reactivity Key	X: Xenopus Z	<ul> <li>H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster</li> <li>X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse</li> <li>GP: Guinea Pig Rab: rabbit All: all species expected</li> </ul>				
Trademarks and Patents	0 0	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.				

Phospho-IKK $\alpha/\beta$  (Ser176/180) Antibody II (#2694) Datasheet Without Images Cell Signaling Technology

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.